Alternatives to Goldspan Health

The widest menu on our list — injections, sublingual lozenges, daily drops, four brand-name pens and the approved oral GLP-1 — with three compounding pharmacies named, prices published for every plan length, and cancellation terms among the most restrictive we have read.

• $49.08 less per month on average than Goldspan Health
• offers FDA-approved brand pens, not just compounded
• has an oral option if you would rather not inject

A women's health brand many mothers already use for birth control or UTIs, now offering GLP-1 care. Its only compounded option is semaglutide drops held under the tongue, $225 for a 28-day bottle, so there is no needle and no compounded tirzepatide. Wisp's own fine print says the drop formula has only been tested on lab tissue, not in people. Brand Wegovy and Zepbound are available for a $99 monthly consult, with the pen bought at your pharmacy, where insurance can help. Drops reach 27 states and DC, and a medical director is named.

• $4.33 less per month on average than Goldspan Health
• offers FDA-approved brand pens, not just compounded
• has an oral option if you would rather not inject

Semaglutide: $199/mo; tirzepatide: Starting at $399/mo. Oral semaglutide starts at $299 and oral tirzepatide at $399; confirm your dose, plan length and cancellation terms.

• $49.08 less per month on average than Goldspan Health
• has an oral option if you would rather not inject
• scores 78/100 against Goldspan Health's 31

Pallas charges $199 every four weeks for compounded semaglutide and $299 for tirzepatide, after first-month offers of $139 and $179. Lower annual-plan averages require a longer commitment; provider care and shipping are included.

• $32.50 less per month on average than Goldspan Health
• offers FDA-approved brand pens, not just compounded
• scores 65/100 against Goldspan Health's 31

A menopause-focused program that bills insurance for eligible visits. The visit is covered in network or $250 self-pay, and the medication is billed separately from $164 per four-week supply — both figures published. It's built for perimenopause, not the postpartum year.

• $70.42 less per month on average than Goldspan Health
• offers FDA-approved brand pens, not just compounded
• scores 72/100 against Goldspan Health's 31

Three pages of this site quote three different prices for the same treatment: the homepage says semaglutide starts at $169 a month, the packages page shows $169 for month one and $199 from month two, and the semaglutide page says the program "typically ranges from $200-$550 per month" — a ceiling nothing on the site comes near. The packages page is the one to trust, and to its credit every plan total on it recomputes to the exact dollar. It also, on the oral semaglutide cards, tells you that what you will receive is tirzepatide.

• $49.08 less per month on average than Goldspan Health
• offers FDA-approved brand pens, not just compounded
• has an oral option if you would rather not inject

A small, physician-led practice — Dr. Tran Le personally, capped at ~500 patients — $199/mo semaglutide, $249/mo tirzepatide, all-inclusive, but limited to Texas and Utah only, with no content addressing postpartum or PCOS.

• $49.08 less per month on average than Goldspan Health
• offers FDA-approved brand pens, not just compounded
• has an oral option if you would rather not inject

Physician-founded and genuinely cheap, with both molecules in a lozenge or a shot and a free MD visit — but a February 2026 FDA misbranding letter is a caveat a mother should read before signing up.

• $119.08 less per month on average than Goldspan Health
• has an oral option if you would rather not inject
• scores 80/100 against Goldspan Health's 31

The most complete set of routes on our list — a real branded lane through insurance or LillyDirect, a compounded lane priced the same at every dose, and a non-GLP-1 generics lane — undercut by a three-day refund window and a complaint pattern that sits squarely on billing.

• offers FDA-approved brand pens, not just compounded
• has an oral option if you would rather not inject
• scores 74/100 against Goldspan Health's 31